Savara Inc. (SVRA)
SVRA Stock Price Chart
Explore Savara Inc. interactive price chart. Choose custom timeframes to analyze SVRA price movements and trends.
SVRA Company Profile
Discover essential business fundamentals and corporate details for Savara Inc. (SVRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Apr 2017
Employees
59.00
Website
https://www.savarapharma.comCEO
Matthew Pauls
Description
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
SVRA Financial Timeline
Browse a chronological timeline of Savara Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.14, while revenue estimate is $2.00m.
Earnings released on 12 May 2026
EPS came in at -$0.15 falling short of the estimated -$0.14 by -7.14%.
Earnings released on 13 Mar 2026
EPS came in at -$0.13 falling short of the estimated -$0.12 by -8.33%.
Earnings released on 12 Nov 2025
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%.
Earnings released on 13 Aug 2025
EPS came in at -$0.14 falling short of the estimated -$0.12 by -16.67%.
Earnings released on 13 May 2025
EPS came in at -$0.12 matching the estimated -$0.12.
Earnings released on 27 Mar 2025
EPS came in at -$0.13 falling short of the estimated -$0.11 by -18.18%, while revenue for the quarter reached $272.00k .
Earnings released on 12 Nov 2024
EPS came in at -$0.11 matching the estimated -$0.11.
Earnings released on 12 Aug 2024
EPS came in at -$0.12 falling short of the estimated -$0.11 by -9.09%.
Earnings released on 9 May 2024
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%.
Earnings released on 7 Mar 2024
EPS came in at -$0.09 surpassing the estimated -$0.11 by +18.18%.
Earnings released on 9 Nov 2023
EPS came in at -$0.10 falling short of the estimated -$0.07 by -42.86%.
Earnings released on 10 Aug 2023
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%.
Earnings released on 15 May 2023
EPS came in at -$0.07 matching the estimated -$0.07.
Earnings released on 30 Mar 2023
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%.
Earnings released on 10 Nov 2022
EPS came in at -$0.07 matching the estimated -$0.07.
Earnings released on 11 Aug 2022
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 11 May 2022
EPS came in at -$0.05 surpassing the estimated -$0.08 by +37.50%.
Earnings released on 30 Mar 2022
EPS came in at -$0.07 matching the estimated -$0.07.
Earnings released on 12 Nov 2021
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%.
Earnings released on 12 Aug 2021
EPS came in at -$0.07 surpassing the estimated -$0.12 by +41.67%.
SVRA Stock Performance
Access detailed SVRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
